News Headlines Article

Merck Drug For Cutting Cholesterol Is Promising
New York Times

Merck has a potential blockbuster in anacetrapib, an experimental cholesterol drug that increases HDL, or “good” cholesterol even as it lowers LDL, the “bad” cholesterol.

The drug could potentially have sales of more than $1 billion a year, John Boris, an analyst at Citigroup, wrote in a note to investors on Wednesday.